Celadon Pharmaceuticals PLC (CEL) — Strategic Asset Allocation Index
Celadon Pharmaceuticals PLC (CEL) has a Strategic Asset Allocation Index of 206.8% as of June 2023. Strategic assets (PP&E of GBX6.27 Million plus long-term investments of GBX-) total GBX6.27 Million, measured against net assets of GBX3.03 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Celadon Pharmaceuticals PLC Strategic Asset Allocation Index (2020–2022)
This chart shows how Celadon Pharmaceuticals PLC's Strategic Asset Allocation Index has evolved across 2 annual periods from 2020 to 2022. As of June 2023, the index stands at 206.8%, representing strategic assets of GBX6.27 Million against net assets of GBX3.03 Million GBX. Explore Celadon Pharmaceuticals PLC operating cash flow efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Celadon Pharmaceuticals PLC (2020–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Celadon Pharmaceuticals PLC from 2020 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see CEL market cap.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 89.2% | GBX6.28 Million | GBX6.28 Million | GBX- | GBX7.04 Million | ▼ -2974.0 pp |
| 2020 | 3063.1% | GBX3.03 Million | GBX3.03 Million | GBX- | GBX99.03K | — |